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Chimeric Antigen Receptor (CAR) T Cell Immunotherapies for 
Leukemias and Lymphomas 




Adoptive cell transfer (ACT) is a rapidly emerging immunotherapeutic approach for cancers. 
This process includes using a patient’s own immune cells and manipulating receptors to fight the 
cancer. The approach with the most significantly positive clinical results has been chimeric 
antigen receptor (CAR) T cell therapy. This includes the method of separating the T cells from 
patients’ blood and using disarmed virus to genetically engineer new receptors on the T cells. 
These artificial receptors allow T cells to bind to antigens on tumor cells to inhibit their growth 
and proliferation. The purpose of this review will be to discuss the typical therapeutic agents for 
cancers such as lymphomas and leukemias as well as introduce the newer approach of CAR-T 
cell immunotherapy. Current clinical outcomes and research in this field, including in canines, 




Acute lymphocytic leukemia (ALL) is the 
most commonly diagnosed cancer in 
children aged birth to 14 years. Acute 
myeloid leukemia (AML) and chronic 
lymphocytic leukemia (CLL) are the most 
common types diagnosed in adults. 
Lymphoma can be divided into two classes: 
Hodgkin lymphoma (HL) and non-Hodgkin 
lymphoma (NHL), with NHL being more 
common. While treatment option for these 
cancers have increased in the past three 
decades, survival rate is still not ideal as the 
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current 5‐year survival rate for ALL is 46% 
for patients aged 20 to 39 years, 30% for 
those aged 40 to 64 years, and 15% for those 
aged 65 years and older (13). Patients who 
have disease that is resistant to 
chemotherapy and stem cell transplantation 
have extremely poor prognoses, and CAR-T 
cell immunotherapy can can provide better 
response rates. 
 
There are two general methods to introduce 
artificial antigen specificity onto T cells to 
create CARs. The first way is to clone T cell 
receptors specific to known antigens and 
enhance their affinity to overcome central 
tolerance. The second way is to utilize single 
chain variable fragments (scFvs) from 
antibodies that attach to known surface 
antigens. These fragments are cloned into an 
expression cassette that incorporates T-cell 
signaling domains and enables T cells to 
respond to human leukocyte antigen 
molecules on antigen presenting cells (7). 
 
CARs are composed of an antigen binding 
domain, a hinge region, an intracellular 
signaling domain, and one or more co-
stimulatory domains. The scFVs derived 
from tumor antigen‐reactive antibodies are 
used as the antigen binding domains. All 
CARs contain the CD3-zeta chain domain as 
the intracellular signaling domain. Second‐ 
or third‐generation CARs improve 
proliferation, cytokine secretion, resistance 
to apoptosis, and in vivo persistence. Second 
generation CARs have been the most used in 
clinical trials. Most of the constructs in the 
second generation utilizes co-stimulatory 
transmembrane domains, like CD28 and 
CD8 to carry out their effects. The CD19-
specific CAR enables CD28 co stimulation, 
which is a key receptor in many clinical 























It is not enough to simply genetically design 
a CAR; is also necessary to transfer specific 
genes into T cells. This can be done through 
gammaretroviral or lentiviral transduction. 
Nonviral gene transfer can also be used 
which is mostly done through 
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transposon/transposase systems techniques 
which already exist such as the Sleeping 
Beauty transposon system. This system 
results in sustained expression of CAR on T 
cells and anti-CD19 transposon CAR T cells 
in early-phase clinical trials. Finally, 
electroporation of T lymphocytes with in 
vitro transcribed RNA can also be done. 
This leads to high but temporary expression 
of the CAR, which is why this method is not 
as often used (3, 4, 7). 
 
In 2017, the first two CAR T cell 
immunotherapies were approved by the 
Food and Drug Administration (FDA). The 
first, tisagenlecleucel (Kymriah™), was 
used in children and adults with advanced 
leukemia. The second, axicabtagene 
ciloleucel (Yescarta™), was utilized in 
patients with large B cell lymphomas (8). 
 
In 2018, James Allison and Takuso Hojono 
won the Nobel Prize in Physiology or 
Medicine for their work in discovering the 
cytotoxic T-lymphocyte antigen 4 (CTLA-4) 
receptor and the programmed death (PD-1) 
molecule on T cells respectively. Blocking 
these two mechanisms has shown to 
decrease tumor sizes by allowing T cells to 
launch better immune attacks against 
various cancers. PD-1 blocking drugs are 
also now approved for lung, kidney, and 
bladder cancers as well as melanomas (6). 
This approach utilizes the intrinsic 
properties of T cells and does not involve 
any genetic engineering like CAR T cell 
therapy. 
 
In 2018 the Food and Drug Administration 
also published a guide on cellular and gene 
therapies in order to propose more guidance 
regarding manufacturing of these drugs and 
improved clinical development. As of 
October 2018, the FDA also had over 700 
active investigational drug applications 
related to gene therapy which shows this is 
one of the fastest growing areas for many 





Ibrutinib is a drug which is traditionally 
used in B cell cancers, such as chronic 
lymphocytic leukemia. This drug binds 
permanently to the protein Bruton’s tyrosine 
kinase (BTK). This kinase normally plays a 
critical role in B cell maturation and mast 
cell activation through IgE receptors. 
However, primary (inherent) and secondary 
(acquired) resistances have been seen while 
using this drug. This may be due to 
mutations which impair the affinity of 
Ibrutinib for BTK or alterations in other 
pathways downstream of BTK. The survival 
of patient’s receiving Ibrutinib is also very 
low with a median three-month survival rate 
after use. For the patient’s that do 
experience success with Ibrutinib, many 
patients relapse within three years of 
treatment (5). 
  
Residual or relapsed lymphomas are often 
treated with oral compounds such as 
cyclophosphamide, which are immune 
suppressors. However, these types of 
compounds can be toxic, which is why it can 
only be used in patients with severe or 
relapsed disease. They also cannot be given 
at very high concentrations and many side 
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effects exist including anemia, emesis, 
thrombocytopenia, allergic reactions and 
pulmonary fibrosis. These types of 
compounds are also not effective in leading 
to complete response. In a clinical trial done 
by Ricconi et. al, 18 patients with 
residual/relapsed lymphoma received 100 
mg oral cyclophosphamide every day for 15 
days every month for six months. Three of 
these patients had no response, ten had 
partial remission and only five had complete 
response. The overall survival in patients 
with aggressive history of cancer was only 
20 months after receiving this treatment 
(13). 
 
Rituximab is another compound which is 
used with non-Hodgkins lymphoma and 
leukemia. Rituximab is an anti CD20 
monoclonal antibody and can play a key role 
in the apoptosis of cancerous B cells, 
especially when used in conjunction with 
compounds such as cyclophosphamide. 
However, not all patients respond equally 
well to rituximab, and in vitro studies has 
shown resistance to rituximab involving the 
anti-complement inhibitors CD55 and 
CD59. This drug also has many unwanted 
side effects including rash, hypotension, 
shortness of breath, leukoencephalopathy, 
and epidermal necrolysis. In a clinical trial 
done by Maury et. al, 209 patients were split 
into two groups and treated with rituximab 
or a control substance. Two-year event free 
survival rates were 65% for the treatment 
group and 52% for the control group, but the 
severe adverse events did not differ 
significantly between the two groups. The 
survival difference is only 7%, but because 
both groups had severe adverse effects, the 
adverse effects do not outweigh the small 
change in survival rate (9). 
 
Finally, stem cell transplantation (SCT) 
including allogenic and autologous can be 
used for treating leukemias and lymphomas. 
Many times, SCT allows a patient to receive 
higher doses of chemotherapeutic drugs as 
severely depleting and damaging the bone 
marrow is less of a concern. In allogenic 
SCT, donors who have a similar human 
leukocytic antigen (HLA) to the patient are 
chosen. These donors are typically family 
members who have close tissue matches to 
the patient. A downside to this method is the 
ability to develop graft-versus-host-disease 
(GVHD) in which the donor’s immune 
system will attack the patient’s own body 
tissues. A major part of the development of 
GVHD is donor T cells recognizing 
recipient minor histocompatibility antigens 
which facilitates an adverse immune 
response. In addition, it can be difficult to 
find a good match if family members are not 
good candidates and utilizing the matched 
unrelated donor method has been linked to 
more complications. In autologous SCT, a 
patient’s own stem cells are removed and 
stored while the patient is receiving 
chemotherapy, and then reinfused after 
completion of treatment. While GVHD is 
not a problem with this method, it can be 
difficult to separate normal stem cells from 
leukemia cells in the bone marrow of the 
patient. A laboratory technique called 
purging is used to remove the leukemia 
cells, but there is still a risk of returning 
some leukemia cells with the SCT (15). 
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A study done by Bleakley et. al was done to 
see if the risk of GVHD could be reduced in 
patients with high risk leukemia. 
Researchers conducted in vitro studies in 
mice to observe the effects of naïve versus 
memory T cells in donor stem cells. It was 
found that the frequency of human CD8+ T 
cells specific for minor H antigens was at 
least 5 to 20-fold higher in naïve T cells 
compared to memory T cells. The naïve T 
cells were then depleted from peripheral 
blood stem cells and implanted into 35 
patients after they had received 
chemotherapy consisting of total body 
irradiation, thiotepa and fludarabine. The 
incidence of acute GVHD did not decrease, 
but there was less amount of chronic GVHD 
(9% of patients). This is compared to 50% 
of chronic GVHD in patients with naïve T 
cell grafts. In addition, including memory T 
cells within the SCT resulted in rapid T cell 
recovery and transfer of protective virus 
specific immunity. The overall survival rate 
of the 35 patients was 78% after two years 
(1). 
 
CD-19 SPECIFIC CAR 
 
CD19 is a type 1 transmembrane protein 
within the immunoglobulin superfamily. 
Functioning of CD19 is dependent on three 
cytoplasmic tyrosine residues – Y391, Y482 
and Y513. Prior experiments have shown 
substituting tyrosine for another amino acid 
leads to inhibition of phosphorylation and 
downstream signaling. CD19 is a biomarker 
used for normal and neoplastic B cells and it 
reduces the threshold required for receptor-
dependent signaling in B cells. Its 
concentration is also three times higher in 
mature B cells compared to immature ones, 
and it is critical in enabling the body to 
mount an immune response. CD19’s 
expression is highly conserved on B cell 
tumors and it is also believed these tumors 
may maintain surface CD19 expression in 
order to amplify transmembrane signals and 
promote their expansion and survival. It is 
also believed that CD19’s autoimmunity 
works via MHC class II receptors in vivo (2, 
16, 17). 
  
Poe et al., showed how c-myc and CD19 
expression worked synergistically to 
influence B cell lymphoma severity. In this 
study Eµ-Myc transgenic (c-MycTg) mice 
which normally develop aggressive and 
lethal B cell lymphomas were made CD19 
deficient (c-MycTgCD19−/−). The CD19 
deficient mice had significantly prolonged 
lifespan (81-83%). This was done through 
reduction in c-Myc phosphorylation at the 
S62, which is a regulatory site that 
contributes to the stability of the c-Myc 
protein. Reduction in c-Myc 
phosphorylation was only seen in CD19−/− 
mice showing that there is a synergistic 
effect between c-Myc and CD19 (12). 
  
The level of CD19 needs to be tightly 
regulated within animal models. It has been 
shown CD19 deficient mice have weak T-
cell dependent humoral responses. In 
addition, total number and frequency of 
peripheral and splenic B cells decreases with 
deficient amounts of CD19. On the other 
hand, over expression of CD19 also 
manifests problems as it is linked with 
greater than 80% reduction in peripheral B 
cells due to impaired generation and 
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development of precursors in the bone 
marrow. Over expression can also 
dramatically alter the levels of 
immunoglobulins in the body. IgG2b levels 
increased by 168%, IgG3 levels decreased 
by 77%, and IgA levels remained 
unchanged. CD19 is also expressed at 
normal to high levels in acute lymphoblastic 
leukemias, chronic lymphocytic leukemias 
(CLL) and B cell lymphomas (12). 
 
CAR-T cell therapy was also found to be 
effective in patients who had already 
received cyclophosphamide (Cy)-based 
lymphodepletion chemotherapy with or 
without fludarabine (Flu). In a study done by 
Turtle et.al, CAR-T cells were manufactured 
from defined T cell subsets and given in a 
one to one ratio of CD4+/CD8+ CAR-T 
cells to patients with relapsed and/or 
refractory B cell non-Hodgkin lymphoma. 
Results showed that there was more 
expansion and persistence of CAR-T cells in 
patients who had received both Cy and Flu 
in the past compared to patients only 
receiving Cy. Complete response was seen 
in 62% of the patients who had received 
both Cy and Flu in the past. It is unclear if 
these results could be seen with other types 




CAR-T cell immunotherapy can also be 
applied to veterinary medicine in dogs. B 
cell lymphomas are the most common 
hematopoietic cancer in dogs and the blood 
systems are conserved in both humans and 
dogs. With the fact that the epidemiology of 
canine cancer is not well known and with 
little data available for how dogs with 
cancer are treated, CAR-T cell 
immunotherapy could be a key therapeutic 
approach to use in veterinary medicine (10). 
 
There are only a handful of FDA approved 
veterinary oncology therapeutics available 
and only one drug available for B cell 
lymphomas (abacfosadine). Typically, dogs 
with high grade lymphomas are treated with 
single agents such as prednisone or 
doxorubicin or combination chemotherapy. 
It has been agreed among veterinary 
oncologists that doxorubicin-based 
combination chemotherapy gives provides 
the longest period of disease control and 
overall survival. Unfortunately, response to 
chemotherapy can most often be suboptimal 
and animals can have recurrent disease. 
Bone marrow transplant is also difficult to 
do in the veterinary setting. Rituximab was 
also used in canines but was not found to be 
effective in binding to or depleting B cell 
lymphocytes (10). 
 
Pankwaj et. all were the first to use mRNA 
electroporation to expand canine T cells ex 
vivo. Artificial antigen-presenting cells 
genetically modified to express human 
CD32 and canine CD86 were used. These 
artificial antigen-presenting cells were 
loaded with a canine CD3 monoclonal 
antibody and used in combination with 
human IL-2 and IL-21 to preferentially 
expand CD8+ T cells in canines. The 
expanded T cells were then injected into a 
dog with relapsed B cell lymphoma. The 
dog tolerated the treatment well, but the 
anti-tumor activity was short lasting (10). 
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Future research is underway to observe the 
clinical efficacy of more stable CAR-T cells 
in order to make anti-tumor activity longer 
lasting (10). 
 
CLINICAL TRIALS IN HUMANS 
 
As mentioned in the introduction, 
tisagenlecleucel was the first anti-CD19 
CAR-T cell therapeutic drug made. This 
drug is still under investigation in pediatric 
and young adult patients with relapsed or 
refractory B cell acute lymphoblastic 
leukemia (ALL). The Children’s Hospital of 
Philadelphia conducted a single-phase study 
of Tisagenlecleucel with 60 children and 
young adults with relapsed or refractory 
ALL. The results from this study showed a 
remission rate of 93% (8). 
 
On the basis of these results, a phase two 
clinical trial was done by Maude et al. on 
five study sites in eleven countries across 
North America, Europe, Asia, and Australia. 
Research participants were 75 patients 
between 3 and 21 years in age and had not 
previously received anti-CD19 therapies. 
Tisagenlecleucel was produced ex-vivo with 
CD137 domain used to provide a 
costimulatory signal along with the CD3-
zeta domain and was infused into patients 
(8). 
 
The overall remission rate was 81% within 
three months of the infusion. These patients 
were also tested for residual minimal disease 
through flow cytometry and were not found 
to have residual disease. Event-free survival 
was 73% at six months and 50% at twelve 
months. Thirty days after tisagenlecleucel 
infusion, 17 of the 75 patients died due to 
relapse ALL or progressed disease (8). 
 
In a study done by Neepalu et al., 
researchers utilized axicabtagene ciloleucel 
(axi-cel) which is an autologous anti CD-19 
CAR. Axicabtagene ciloleucel was the 
second CAR-T cell immunotherapeutic 
agent approved by the FDA in 2017. This 
drug has a single-chain variable fragment 
extracellular domain targeting CD19 
proteins with CD3-zeta and CD28 co-
stimulatory domains. Prior to this study, 
single institution studies, such as at the 
National Cancer Institute, have found that 
many responses to axi-cel and other anti-
CD19 CARs have been ongoing beyond 4 
years, which suggests that this therapy may 
be potentially curative for lymphomas. This 
study was done in patients who did not see 
any progress with conventional treatments. 
101 patients with diffuse large B cell 
lymphoma, primary mediastinal B cell 
lymphoma, and transformed follicular 
lymphoma were enrolled in a phase two 
clinical trial (11). 
 
Patients received a target dose of 2×106 
anti-CD19 CAR T cells per kilogram of 
body weight. 85% of the patients receiving 
this treatment had stage III or VI cancer and 
69% had received at least three prior 
therapies which were not effective. 82% of 
the patients who were treated had an 
objective response, and 54% had a complete 
response. Researchers followed up with the 
patients 15 months later and saw responses 
ongoing in 42% of the patients. 40% of the 
patients still had complete response 15 
months after treatment. 52% of the patients 
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had also survived 18 months post treatment. 
Three of the patients died during the 
treatment. The median duration of response 
was 11.1 months and the median duration of 





Like the traditional chemotherapeutic agents 
used for leukemias and lymphomas, severe 
side effects can also occur with the use of 
CAR-T cell therapy. In the tisagenlecleucel 
study, 73% patients experienced grade three 
or four adverse events which were directly 
related to the use of the T cell therapy. The 
most common event being severe cytokine 
release syndromes which included increases 
interleukin-6, interferon gamma, and ferritin 
levels. Higher grade cytokine release 
syndromes were also associated with more 
neurological side effects. Other common 
side effects were hypotension, and decreased 
lymphocyte count. All patients who 
responded to the treatment also developed B 
cell aplasia and had to be given 
immunoglobulin replacement. Six months 
after infusion, B cell aplasia continued to 
persist in 83% of patients (8). 
 
In the axi-cel study, the most common 
adverse events 3 were pyrexia (85%), 
neutropenia (78%), anemia (43%), and 
thrombocytopenia (38%). Grade 3 or higher 
cytokine release syndrome occurred in 13%. 
Compared to the Tisagenlecleucel study, 
there were less patients with cytokine 
release syndrome. Patient’s with cytokine 
release syndrome did respond well to 
vasopressors. There were more neurological 
symptoms with axi-cel than 
Tisagenlecleucel. 64% of patients 
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experienced neurological symptoms with 
25% percent of patients experiencing grade 
three or higher neurologic symptoms. The 
most common grade three or higher 
symptoms included encephalopathy, 
confusion and aphasia. However, the median 
onset of these neurological symptoms was 
on day 5, with median resolution on day 17. 
The prevalence of cytokine release 
syndromes and neurological symptoms also 
decreased during the course of the study. 
Three of the patients died during treatment 
(11). 
 
However, the difference with this type of 
therapy is that additional therapy was not 
needed. Patient’s only received one single 
infusion of tisagenlecleucel or axi-cel 
without the need for SCT or other oral 
compounds. Many of the adverse side 
effects were mitigated through supportive 
measures such as utilizing tocilizumab, a 
monoclonal antibody against IL-6, for the 
cytokine release syndromes and 




To conclude, CAR T-Cell therapy has been 
effective in many patients with leukemia and 
lymphoma in inducing remission and 
improved symptoms. This type of therapy is 
most popular in patients in which typical 
therapies have not been effective. CAR T-
Cell drugs have also been approved by the 
FDA, but unwanted side effect profiles 
continue to be a problem with this type of 
therapeutic agent. These treatments are also 
very cost prohibitive and the criteria to 
qualify to obtain the treatment is very 
stringent. However, research in this field 
continues to become more popular and is 
advancing rapidly (8, 11). 
 
Future directives in this field have already 
began. A newer approach is the 
development of CAR T cell therapies which 
use immune cells collected from healthy 
donors instead of cancer patients. The goal 
of this is to create CAR T cell therapies 
which can be readily available for use 
instead of manufacturing therapies 
individually for each patient, which can be 
both expensive and time consuming. The 
French company Cellectis, has launched a 
phase I trial of this type of CD19-targeted 
CAR T-cell product in the United States for 
patients with advanced acute myeloid 
leukemia. Cellectis uses a gene-editing 
technology known as TALEN which has 
already been tested in Europe, including in 
two infants with ALL who had already gone 
through all of the available therapeutic 
options. In both instances, the treatment was 
effective. It will be important to continue to 
use CAR-T cells from donor patients in a 
larger sample size to look at efficacy. 
 
Numerous other researchers are also looking 
to develop CAR T cells in vivo with the 
ability to turn the cells “off or on” with the 
hope of relieving unwanted side effects. In 
addition, utilization of CRISPR/Cas 9 
systems are also being considered to more 
precisely engineer T cells. So far, this type 
of therapy has not been effective against 
solid tumors, but researchers are looking to 
develop more advanced T cells which would 
be able to penetrate solid tumors.
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